Technical Evaluation of Lenivia (Izenivetmab) and Portela (Relfovetmab)

Cat Picture

Executive Summary

This report provides a comprehensive technical evaluation of two next-generation monoclonal antibody (mAb) products from Zoetis: Lenivia (izenivetmab) and Portela (relfovetmab). Both products belong to the anti-nerve growth factor (anti-NGF) mAb class, a category of biologics that has reshaped the management of chronic osteoarthritis (OA) pain in companion animals by providing long-duration analgesia from a single injection. The two products, however, are not interchangeable: Lenivia is approved for alleviation of OA pain in dogs (Health Canada, October 15, 2025) (Zoetis press release), whereas Portela is approved for alleviation of OA pain in cats (European Commission marketing authorization, October 2025; CVMP positive opinion, September 2025) (Zoetis CVMP opinion; Zoetis EC authorization). Both deliver approximately three months of clinically meaningful pain relief per subcutaneous injection, but they target different species, have distinct safety profiles, and represent complementary additions to Zoetis's existing canine (Librela/bedinvetmab) and feline (Solensia/frunevetmab) anti-NGF franchises. The principal findings of this evaluation are summarized in the comparative analysis section, with detailed knowledge gaps and research recommendations presented at the end.

⚠️ Fact-check note — EC authorization date: The original report cited “October 2025” for the Portela EC marketing authorization. The precise date is October 29, 2025, per Zoetis's official press release.

⚠️ Fact-check note — Portela Health Canada approval omitted: The original report stated that Health Canada status for Portela was undocumented. This is now outdated: Health Canada approved Portela in December 2025, with commercial availability in Canada anticipated in 2026. This finding closes knowledge gap #1 (partially) and knowledge gap #5 (intra-species regulatory data) as noted in Section 5.

1. Background: The Anti-NGF mAb Class in Veterinary Medicine

Before evaluating the two products individually, it is worth framing the therapeutic class to which they belong. Anti-NGF monoclonal antibodies target nerve growth factor, a neurotrophin that sensitizes nociceptive neurons and amplifies pain signaling in chronic joint disease. In OA, elevated synovial NGF levels drive peripheral and central sensitization, producing the chronic pain that limits mobility and quality of life in affected animals. By selectively binding circulating NGF, anti-NGF mAbs interrupt this cascade at a well-defined mechanistic node, providing analgesia without the gastrointestinal, renal, and hepatic liabilities of long-term non-steroidal anti-inflammatory drug (NSAID) use — a particularly meaningful advantage in cats, where NSAID options are limited, and in older dogs with comorbidities.

Within Zoetis's portfolio, this mechanism is now represented across four approved products: bedinvetmab (Librela, canine, monthly dosing), izenivetmab (Lenivia, canine, ~three-month dosing), frunevetmab (Solensia, feline, monthly dosing), and relfovetmab (Portela, feline, three-month dosing). The arrival of Lenivia and Portela marks a clear strategic shift: the same anti-NGF mechanism is being extended into a new, longer-duration dosing paradigm in both species. The fact that each species now has both a monthly and a quarterly anti-NGF option reflects real-world demand from veterinarians and pet owners for less frequent clinic visits, improved compliance, and sustained analgesia.

2. Lenivia (Izenivetmab)

2.1 Product Overview and Regulatory Status

Lenivia is a long-acting anti-NGF monoclonal antibody developed by Zoetis for the alleviation of pain associated with osteoarthritis in dogs. The most recent and well-documented regulatory milestone is Health Canada's approval on October 15, 2025, as announced in Zoetis's official press release (Zoetis press release). The consulted sources do not document Lenivia's regulatory status with the U.S. FDA, the European Medicines Agency, or any other major jurisdiction, which represents a notable knowledge gap and an obvious area for further research.

2.2 Mechanism of Action

Lenivia is described in the source material as an anti-NGF monoclonal antibody that binds NGF at a different epitope than Zoetis's earlier canine anti-NGF product, Librela (bedinvetmab) (Zoetis press release). This is a technically significant differentiator. Epitope selection influences binding affinity, on-rate/off-rate kinetics, the precise structural region of NGF that is occluded, and potentially the immunogenicity profile and the breadth of NGF species recognized. From a clinical standpoint, the epitope shift is the most plausible explanation for why Lenivia could be positioned as a distinct successor or alternative to Librela rather than as a me-too biologic. It is also consistent with the broader trend in mAb engineering, in which second-generation products often differentiate on epitope, Fc engineering, glycosylation, or formulation.

2.3 Pharmacokinetics and Dosing

The press release specifies that Lenivia is administered by subcutaneous injection and provides approximately three months of OA pain alleviation per dose (Zoetis press release). This duration is consistent with the typical pharmacokinetic behavior of long-acting veterinary mAbs, which exploit the slow clearance and FcRn-mediated recycling of IgG molecules to extend exposure. The consulted source does not, however, disclose specific PK parameters such as Cmax, Tmax, elimination half-life, or absolute bioavailability. These values are typically published in the regulatory assessment report (e.g., the European Public Assessment Report or the Health Canada product monograph) and in peer-reviewed pharmacology papers; their absence here is a gap that should be addressed in a more in-depth regulatory submission review.

2.4 Efficacy

The efficacy claim for Lenivia rests on a nine-month field study in dogs, which the press release describes as demonstrating increased mobility and decreased pain (Zoetis press release). A nine-month duration is meaningful in this context because it covers three full dosing intervals, allowing assessment of sustained efficacy, repeat-dose pharmacokinetics, and the durability of effect over an entire OA management cycle. The press release does not describe the primary endpoint in detail (e.g., owner-reported pain scores such as the Canine Brief Pain Inventory, veterinary clinical metrology instruments, or actimetry-based objective measures), nor does it report effect size or statistical significance. These details would be expected in a peer-reviewed publication or a regulatory document.

2.5 Safety Profile

The Health Canada approval press release enumerates several adverse effects associated with Lenivia: balance problems, weakness, decreased appetite, vomiting, diarrhea, polydipsia (increased thirst), and polyuria (increased urination) (Zoetis press release). This profile is dominated by systemic and gastrointestinal signs rather than the dermatologic/injection-site signs more typical of feline anti-NGF mAbs. The press release also specifies three explicit contraindications: hypersensitivity to izenivetmab, use in breeding/pregnant/lactating dogs, and dogs under 12 months of age (Zoetis press release). The age cutoff is a standard precaution in canine biologics because the developing nervous system depends on NGF signaling, and the breeding/pregnancy contraindication reflects the standard precautionary approach for products lacking targeted reproductive safety studies. Notably, the press release does not discuss use in dogs with concurrent chronic kidney disease (CKD), which is a key comorbidity in older dogs with OA. Whether the canine product's safety in CKD has been formally evaluated remains an open question.

3. Portela (Relfovetmab)

3.1 Product Overview and Regulatory Status

Portela is a novel, long-acting anti-NGF monoclonal antibody developed by Zoetis for the alleviation of pain associated with osteoarthritis in cats. The most significant regulatory milestone is the European Commission's marketing authorization in October 2025, following a CVMP positive opinion in September 2025 (Zoetis EC authorization; Zoetis CVMP opinion). The EMA product record (product number EMEA/V/C/005890, CVMP reference EMA/CVMP/285092/2025, page last updated 05/11/2025) classifies Portela within the nervous system / analgesic-antipyretic therapeutic category (EMA Portela EPAR). Commercial availability in the EU is anticipated in 2026 (Zoetis EC authorization). The press releases do not indicate FDA or Health Canada status for Portela.

⚠️ Fact-check — Portela Health Canada approval (new information): The original report stated that Health Canada status for Portela was not documented in the consulted sources. This is now outdated. Health Canada approved Portela (relfovetmab injection) in December 2025, with commercial availability in Canada anticipated in 2026 alongside the EU launch. This closes the stated knowledge gap regarding Health Canada status.

⚠️ Fact-check — EC date: The EC authorization date is specifically October 29, 2025, not merely “October 2025.”

3.2 Mechanism of Action

Portela is an anti-NGF mAb, mechanistically analogous to Solensia (frunevetmab) but with a pharmacokinetic profile that supports a substantially longer dosing interval. The CVMP opinion press release positions Portela as the first long-acting (three-month dosing interval) anti-NGF mAb therapy for cats (Zoetis CVMP opinion). Whether Portela binds a different NGF epitope than Solensia, comparable to the Lenivia-vs-Librela distinction, is not stated in the consulted sources. This is a worthwhile target for further research and would clarify the molecular basis for the differentiated dosing interval.

❌ Fact-check — Significant error corrected: The original report stated that whether Portela binds a different NGF epitope than Solensia “is not stated in the consulted sources” and flagged this as a knowledge gap requiring further research. This is incorrect. The Health Canada approval press release for Portela (December 2025) explicitly states: “Like Solensia, Portela is a monoclonal antibody that targets nerve growth factor (NGF); however, Portela is designed to alleviate pain associated with OA for a longer period of time by binding to a different site on NGF.” This fact was publicly available in Zoetis's own press materials and was missed by the original research. Knowledge gap #3 in Section 5 is therefore already resolved.

3.3 Pharmacokinetics and Dosing

The press releases describe Portela as an injectable therapy offering three months of OA pain relief per single injection (Zoetis EC authorization). The route of administration is described as “injection”; the more specific subcutaneous route is consistent with the mAb class but is not explicitly stated in the press releases. As with Lenivia, specific PK parameters (Cmax, Tmax, half-life, bioavailability) are not disclosed in the consulted sources, although the EMA EPAR typically contains a comprehensive summary of product characteristics that would include these data.

3.4 Efficacy

The efficacy profile of Portela was demonstrated in a nine-month European field trial, importantly including cats with IRIS stage 1, 2, or 3 kidney disease (Zoetis CVMP opinion; Zoetis EC authorization). The explicit inclusion of CKD cats is a clinically important design choice. OA and CKD frequently co-occur in older cats, and conventional analgesic options such as NSAIDs are often contraindicated or require careful monitoring in CKD. The CVMP's positive opinion was based on a favorable benefit–risk assessment that integrated both efficacy and tolerability data, which is a strong external signal of regulatory confidence.

3.5 Safety Profile

Portela is described as well-tolerated in clinical trials, including in cats with IRIS stage 1–3 kidney disease (Zoetis CVMP opinion; Zoetis EC authorization). This tolerability in CKD is a distinguishing safety claim that addresses a major unmet clinical need. The adverse event profile documented in the EC authorization press release is more granular than the Lenivia profile and is presented in a frequency-stratified format: immediate injection pain (>1 in 10 cats; very common), dermatitis (up to 1 in 10; common), and — uncommonly (up to 10 in 1,000) — pruritus, skin scabs, injection site swelling, and hair loss (Zoetis EC authorization).

The press release also provides comparative context by listing the labeled AE profile of the related monthly product, Solensia (frunevetmab): hair loss, dermatitis, and itching (up to 1 in 10); rare injection site reactions and skin lesions (up to 1 in 1,000); and very rare anaphylaxis (up to 1 in 10,000) (Zoetis CVMP opinion). The AE profiles of Portela and Solensia are broadly similar in qualitative nature (predominantly dermatologic and injection-related), with the standout difference being the very common (>1 in 10) immediate injection pain reported for Portela. Whether this is a function of the formulation, the injection volume, the route (subcutaneous versus alternative), or the population studied is not specified in the consulted material.

3.6 Unmet Need Context

The EC authorization press release frames the market opportunity with a striking statistic: up to 40% of cats are estimated to have clinical signs of OA, but only 18% are diagnosed (Zoetis EC authorization). This implies that the majority of affected cats are undiagnosed and therefore untreated. The diagnostic gap is itself a barrier to optimal care, and any product that reduces the practical burden of treatment (e.g., a 3-month dosing interval) has the potential to lower the threshold for both veterinarians and owners to initiate and maintain therapy.

4. Comparative Analysis

4.1 Side-by-Side Technical Comparison

The table below summarizes the principal technical attributes of each product, drawing on the evidence reviewed above.

Parameter Lenivia (Izenivetmab) Portela (Relfovetmab)
Sponsor Zoetis Zoetis
Drug class Anti-NGF monoclonal antibody Anti-NGF monoclonal antibody
Target species Dogs Cats
Indication Alleviation of OA pain Alleviation of OA pain
Route Subcutaneous injection Injection (subcutaneous; inferred)
Dosing interval ~3 months 3 months
Key mechanistic differentiator Binds a different NGF epitope than Librela (bedinvetmab) First long-acting (3-month) anti-NGF mAb for cats
Key efficacy data 9-month field study in dogs 9-month European field trial, including IRIS stage 1–3 CKD cats
Notable safety findings GI signs (vomiting, diarrhea), polydipsia/polyuria, weakness, balance problems; not for <12 mo, breeding, pregnant, lactating Well-tolerated in CKD cats; most common AE: immediate injection pain (>1 in 10); dermatitis (up to 1 in 10)
Primary regulatory milestone Health Canada approval (Oct 15, 2025) EU EC marketing authorization (Oct 2025); commercial launch 2026
Companion product in same species Librela (bedinvetmab) — earlier canine anti-NGF mAb Solensia (frunevetmab) — monthly feline anti-NGF mAb

4.2 Interpretive Observations

First, both products are class- and sponsor-aligned but species-segregated. They share the same mechanism (anti-NGF), the same sponsor (Zoetis), and a common three-month dosing interval, but they are indicated for different species and are therefore not head-to-head competitors. Each is best understood as the long-acting member of its species-specific anti-NGF pair, sitting alongside the shorter-acting predecessor.

Second, the two products reflect a coherent portfolio strategy. In dogs, Librela established the anti-NGF category and Lenivia extends it into a quarterly dosing paradigm with a distinct epitope. In cats, Solensia established the anti-NGF category and Portela extends it into a quarterly dosing paradigm. This pairing — monthly predecessor and quarterly successor — gives Zoetis flexibility to address owner compliance preferences, clinic workflow constraints, and case-by-case clinical considerations within each species.

Third, dosing interval is a shared convenience/efficacy feature. Both products offer approximately three months of OA pain alleviation per injection, which represents a meaningful practical advantage over monthly dosing in terms of clinic visits, pet stress, and total injection burden. The fact that the two products reached the same dosing interval in two different species suggests that the underlying pharmacokinetic optimization (e.g., dose strength, Fc engineering, formulation) has converged on a similar exposure target, even though the molecular details of the antibodies themselves differ.

Fourth, safety profiles are species-distinct and clinically logical. The canine Lenivia adverse event profile is dominated by systemic and gastrointestinal signs (vomiting, diarrhea, polydipsia, polyuria, weakness, balance problems), whereas the feline Portela profile is dominated by local and injection-related signs (immediate injection pain, dermatitis, pruritus, skin scabs, injection site swelling, hair loss). This divergence mirrors species-specific patterns seen in the prior anti-NGF products (Librela and Solensia) and likely reflects both species differences in mAb handling and differences in how adverse events are reported and categorized. The explicit demonstration of tolerability in IRIS stage 1–3 CKD cats is a particularly important Portela claim, because the high prevalence of CKD in older cats makes NSAID-sparing analgesic options especially valuable in this population.

Fifth, regulatory geographies differ at this snapshot in time. As of late 2025, Lenivia's first major approval is in Canada, while Portela's first is in the European Union. The two products are therefore at different points in their global regulatory rollouts. It is also notable that the FDA approval status for either product is not documented in the consulted sources, which is a significant information gap given the size of the U.S. veterinary biologics market.

4.3 Agreement and Disagreement Among Sources

The consulted sources are in close agreement on the principal facts: both are anti-NGF mAbs, both are administered by injection at approximately three-month intervals, both target OA pain, and both are developed by Zoetis. The CVMP opinion press release and the EC authorization press release are mutually consistent in their descriptions of Portela's mechanism, indication, dosing, and tolerability. The Health Canada approval press release is the sole source for Lenivia and is internally consistent.

There are minor areas of variation in emphasis. The EC authorization press release provides the most granular safety data (frequency-stratified AE categories), while the Health Canada approval press release provides a more qualitative list of AEs. The CVMP opinion press release includes comparative AE data for the related product Solensia, which the EC authorization press release does not restate. None of the sources conflict on the core technical facts, but the granularity of safety reporting is clearly higher for Portela than for Lenivia, likely reflecting differences in the maturity of the regulatory dossiers and the stage of approval.

5. Knowledge Gaps and Recommendations for Further Research

This technical evaluation is based primarily on Zoetis press releases and a single EMA EPAR landing page. Several important questions remain unanswered:

  1. Regulatory status outside Canada (Lenivia) and outside the EU (Portela). FDA, EMA (for Lenivia), Health Canada (for Portela), and other major jurisdiction approvals were not located in the consulted sources. A targeted search of FDA CVM approvals and Health Canada's Veterinary Drugs Directorate database would close this gap.

  2. Detailed product labels / SPCs. The European Summary of Product Characteristics for Portela and the Health Canada product monograph for Lenivia would provide precise posology, withdrawal periods (if applicable), full AE tabulations, contraindications, and precautions that are not fully captured in press releases.

  3. Molecular and epitope characterization. Whether Portela binds a different NGF epitope than Solensia — analogous to the documented Lenivia vs. Librela distinction — is not stated in the consulted sources. Peer-reviewed structural or epitope-mapping publications, if available, would resolve this.

  4. Pharmacokinetic parameters. Cmax, Tmax, half-life, and bioavailability are not disclosed in the press releases. These values are typically available in regulatory assessment reports and peer-reviewed pharmacology publications.

  5. Comparative intra-species data. Head-to-head comparisons between Lenivia and Portela are biologically impossible (different species), but intra-species comparisons — Lenivia vs. Librela in dogs, and Portela vs. Solensia in cats — would be highly informative and likely exist in regulatory dossiers or peer-reviewed literature.

  6. Source quality filtering. Several URLs encountered during research (L'Oréal hair-color product pages) were entirely unrelated to veterinary therapeutics and were excluded. This illustrates the need for targeted search queries using INNs (izenivetmab, relfovetmab) and brand names (Lenivia, Portela) to avoid spurious results.

6. Conclusion

Lenivia (izenivetmab) and Portela (relfovetmab) are two new long-acting anti-NGF monoclonal antibodies from Zoetis that collectively extend the anti-NGF therapeutic class into a quarterly dosing paradigm in both companion-animal species most affected by osteoarthritis. Lenivia, approved by Health Canada on October 15, 2025, is indicated for alleviation of OA pain in dogs, binds a different NGF epitope than Librela (bedinvetmab), and is administered by subcutaneous injection at approximately three-month intervals, with efficacy supported by a nine-month field study (Zoetis press release). Portela, granted European Commission marketing authorization in October 2025 following a September 2025 CVMP positive opinion, is indicated for alleviation of OA pain in cats, is the first long-acting (three-month) anti-NGF mAb for felines, and demonstrated efficacy and tolerability in a nine-month European field trial that included cats with IRIS stage 1–3 chronic kidney disease (Zoetis CVMP opinion; Zoetis EC authorization; EMA Portela EPAR).

In direct answer to the question: the two products are technically aligned in class and dosing interval but are not interchangeable. They are species-specific products, each occupying the long-acting slot in a paired portfolio that also includes an earlier monthly anti-NGF mAb (Librela in dogs, Solensia in cats). For veterinary decision-makers, the practical significance is that the anti-NGF option set in each species has expanded, with the new three-month products offering improved convenience and — in the feline case — demonstrated tolerability in the clinically important CKD subpopulation. For regulators, payers, and researchers, the principal outstanding questions concern the molecular basis for the dosing-interval extension, the full safety dataset, and the geographic expansion of approvals beyond Canada (for Lenivia) and the EU (for Portela).

Raw Findings

Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab ...

Source: https://news.zoetis.com/press-releases/press-release-details/2025/Zoetis-Announces-Health-Canada-Approval-of-Lenivia-izenivetmab-injection-for-Alleviation-of-Osteoarthritis-OA-Pain-in-Dogs/default.aspx The webpage provides comprehensive technical information about Lenivia (Izenivetmab) through a Zoetis press release dated October 15, 2025, announcing Health Canada approval. Key technical details include: Lenivia is a long-acting monoclonal antibody therapy that binds to nerve growth factor (NGF) at a different binding site than Librela (bedinvetmab), providing three months of OA pain alleviation per subcutaneous injection. Its safety profile was demonstrated in a nine-month field study showing increased mobility and decreased pain. Contraindications include hypersensitivity to izenivetmab, breeding/pregnant/lactating dogs, and dogs under 12 months. Reported adverse effects include balance problems, weakness, decreased appetite, vomiting, diarrhea, polydipsia, and polyuria. Notably, the webpage contains NO information about Portela (Relfovetmab)—this product is not mentioned anywhere in the content, so a complete technical evaluation of Portela cannot be supported by this source alone.

Long-acting therapy for relieving OA pain in cats receives European marketing authorization | dvm360

Source: https://www.dvm360.com/view/long-acting-therapy-for-relieving-oa-pain-in-cats-receives-european-marketing-authorization The provided webpage content contains only navigation menu elements and no substantive information that can be used to perform a technical evaluation of Lenivia (Izenivetmab) or Portela (Relfovetmab). No relevant evidence regarding mechanism of action, clinical trial data, pharmacokinetics, indications, safety, efficacy, or comparative analysis could be extracted. To fulfill the user's goal, additional webpage content containing actual articles or technical documents about these veterinary monoclonal antibody therapies would be required.

Zoetis – Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Source: https://news.zoetis.com/press-releases/press-release-details/2025/Zoetis-Receives-Positive-Opinion-from-CVMP-for-Portela-relfovetmab-to-Alleviate-Pain-Associated-with-Osteoarthritis-in-Cats/default.aspx This webpage provides comprehensive technical information about Portela® (relfovetmab) for use in a technical evaluation, but contains no information on Lenivia (Izenivetmab). Portela is a novel anti-nerve growth factor (anti-NGF) monoclonal antibody developed by Zoetis for the alleviation of pain associated with osteoarthritis (OA) in cats. Its key technical differentiator is its long-acting formulation, providing three months of pain relief per single injection, making it the first long-acting anti-NGF mAb therapy for cats if approved. The CVMP of the EMA issued a positive opinion in September 2025 based on favorable benefit-risk data; clinical trials showed it to be well-tolerated, even in cats with IRIS stage 1-3 kidney disease, and effective in alleviating OA pain. Portela joins Zoetis's existing OA pain franchise alongside Solensia® (frunevetmab), an anti-NGF mAb indicated for monthly OA pain alleviation in cats and approved in 40+ countries. Solensia's safety profile includes common side effects of hair loss, dermatitis, and itching (up to 1 in 10), rare injection site reactions and skin lesions (up to 1 in 1,000), and very rare anaphylaxis (up to 1 in 10,000). Portela is expected to receive European Commission approval in Q4 2025, with commercial availability in the EU anticipated in 2026. Notably, the article does not mention Lenivia (Izenivetmab), so a direct side-by-side technical comparison cannot be made from this source.

Zoetis – Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Source: https://news.zoetis.com/press-releases/press-release-details/2025/Zoetis-Receives-European-Commission-Marketing-Authorization-for-Portela-relfovetmab-to-Alleviate-Pain-Associated-with-Osteoarthritis-in-Cats/default.aspx The webpage provides comprehensive technical information on Portela® (relfovetmab) for a technical evaluation: (1) Drug Class & Mechanism: Portela is a monoclonal antibody (mAb) targeting anti-nerve growth factor (NGF), a key mediator of OA pain and inflammation in cats. (2) Dosing Regimen: First mAb therapy with a three-month dosing interval, providing three months of OA pain relief per single injection. (3) Regulatory Status: Received European Commission marketing authorization (October 2025) following a positive CVMP recommendation in September 2025, with commercial availability in the EU anticipated in 2026. (4) Clinical Efficacy/Safety: Demonstrated effectiveness and tolerability in a nine-month European field trial, including in cats with IRIS stage 1, 2, or 3 kidney disease. (5) Side Effects: Most common is immediate injection pain (>1 in 10 cats), followed by dermatitis (up to 1 in 10), with uncommon effects (up to 10 in 1,000) including pruritus, skin scabs, injection site swelling, and hair loss. (6) Comparison Context: Portela joins Zoetis's Solensia® (frunevetmab), a monthly anti-NGF mAb already approved in 40+ countries, establishing Portela as a longer-acting alternative within the same therapeutic class. (7) Unmet Need: Up to 40% of cats have clinical OA signs, but only 18% are diagnosed, highlighting a significant market and clinical need. Important limitation: The webpage contains no information on Lenivia (Izenivetmab); a complete technical evaluation of both products would require additional sources covering Lenivia.

Portela | European Medicines Agency (EMA)

Source: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/portela The webpage contains detailed regulatory information for Portela (Relfovetmab), a veterinary medicinal product authorised in the European Union. Key details include: it is a nervous system analgesic/antipyretic, assigned EMA product number EMEA/V/C/005890, with a CVMP positive opinion (reference EMA/CVMP/285092/2025) issued in September 2025. The CVMP meeting highlights were published on 12/09/2025, and the page was last updated on 05/11/2025. Full product information is available on the Veterinary Medicines Information website. Notably, the webpage contains no information about Lenivia (Izenivetmab), meaning only partial fulfillment of the user's stated goal is possible from this content.

Sources

-Jens